The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study
|
|
- Brenda Skinner
- 5 years ago
- Views:
Transcription
1 Respiratory Medicine (2007) 101, The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study Mario Cazzola a,,1, Maria Gabriella Matera b a Department of Respiratory Medicine, Unit of Pneumology and Allergology, A. Cardarelli Hospital, Naples, Italy b Department of Experimental Medicine, Unit of Pharmacology, 2nd University of Naples, Naples, Italy Received 30 August 2006; accepted 9 September 2006 Available online 23 October 2006 KEYWORDS COPD; Tiotropium; Formoterol; Theophylline; Combination therapy Summary We explored the additive effect of titrated oral theophylline in patients with stable chronic obstructive pulmonary disease (COPD) who received both tiotropium, 18 mg od, and formoterol, 12 mg bid. Thirty-six patients with moderate-to-severe COPD were enrolled in this two-period trial. They were initially treated with formoterol+tiotropium for 4. After this first period, they were divided in two groups of 18 patients. Both groups continued with the initial treatment for further 4, but the first group received also placebo whereas the second group received oral theophylline. The combination therapy with formoterol+tiotropium induced a significant improvement in mean predose FEV 1 and FVC at the end of the first period, and a significant reduction in dyspnea score as measure by a visual analogic scale and in use of rescue salbutamol. The second period of treatment elicited a significant further improvement in lung function and reduction in dyspnea score and salbutamol use in both groups. On the contrary, differences in improvements in FEV 1 and FVC and reduction in dyspnea score and salbutamol use between theophylline and placebo arms at the end of the second treatment period were not significant, although 5 patients reported an important relief in dyspnea during the theophylline administration period. These findings question the importance of adding theophylline in stable COPD patients already treated with two long-acting bronchodilators, but also indicate the possibility that some of them can benefit from theophylline because of a symptomatic improvement. & 2006 Published by Elsevier Ltd. Corresponding author. address: mcazzola@qubisoft.it (M. Cazzola). 1 Present address: Department of Internal Medicine, Unit of Respiratory Diseases, University of Rome Tor Vergata, Rome, Italy. Introduction Current evidence supports the recommendation of the Global Initiative for chronic obstructive lung disease (GOLD) guidelines 1 and American Thoracic Society/European /$ - see front matter & 2006 Published by Elsevier Ltd. doi: /j.rmed
2 958 M. Cazzola, M.G. Matera Respiratory Society position paper 2 of at least one of the two classes of long-acting inhaled bronchodilators, either oncedaily tiotropium or twice-daily salmeterol or formoterol, as initial maintenance therapy for symptomatic chronic obstructive pulmonary disease (COPD). There is no data supporting the superiority of one of the families of inhaled bronchodilators (i.e., b2 agonists and anti-cholinergic agents) over the other. Thus, the choice has to be based on the individual symptomatic response. In patients who do not respond satisfactorily to tiotropium or a long-acting inhaled b-agonist as the initially prescribed single maintenance agent, the GOLD guidelines recommend the addition of the alternate class of long-acting inhaled bronchodilator as the next step. In effect, an increasing body of evidence 3 7 indicates that the combination of a long-acting b 2 -agonsit and a long-acting anti-muscarinic agent is an effective therapeutic approach for patients suffering from moderate-to-severe COPD. Unfortunately treatments prescribed for COPD patients do not always follow current guidelines, particularly in the primary care setting. Recently, Taskin et al. 8 have examined the adherence to GOLD guidelines recommendation among patients entering UPLIFT, a global trial evaluating the efficacy of tiotropium in slowing COPD progression and have observed that the percentage of patients receiving longacting bronchodilators increased as COPD severity increased; however, a substantial number of patients were not receiving long-acting bronchodilators in accordance with GOLD guidelines. In particular, long-acting bronchodilators (anti-cholinergics and/or b-agonists) were used in 67.3% and 69.3% of patients. The use of theophylline in 34.9% and 36.1% patients suffering from severe and very severe COPD, respectively, was another unexpected finding. Theophylline, which used to be part of the mainstay of treatment for COPD, has been relegated to third-line therapy in COPD because of the frequency of side effects and relative low efficacy. 9 Nonetheless, it is inexpensive and still has its role. In fact, theophylline tends to be added to these inhaled bronchodilators in more severe patients and has been shown to give additional clinical improvement when added to a long-acting b 2 -agonist. 10,11 Moreover, increasing evidence shows that theophylline has significant anti-inflammatory effects in COPD at lower plasma concentrations. 12 In particular, Barnes 12 has highlighted that it is the only therapy currently available that is anti-inflammatory in patients with COPD. These findings are important and might justify the body of evidence that supports the use of theophylline together with a b 2 -agonist and an anti-cholinergic because a number of patients with COPD may respond subjectively to theophylline. In effect, GOLD guidelines 1 report that the combination of a b 2 -agonist, an anti-cholinergic, and theophylline may produce additional improvements in lung function and heath status. We examined the additive effect of oral theophylline in patients with stable COPD who received both tiotropium, 18 mg od, and formoterol, 12 mg bid in a regular manner. Patients and methods Thirty-six patients with well-controlled moderate-to-very severe COPD were enrolled. All of them were 50 years of age or older, and were current or former smokers with a 20 packyear or more history. Inclusion criteria required a baseline FEV 1 of less than 70% of predicted but more than 0.50 L, and a postbronchodilator FEV 1 /FVC o70% following salbutamol, 400 mg. Exclusion criteria were as follows: current evidence of asthma as primary diagnosis; unstable respiratory disease requiring oral/parenteral corticosteroids within 4 prior to beginning the study; upper or lower respiratory tract infection within 4 of the screening visit; unstable angina or unstable arrhythmias; concurrent use of medications that affected COPD or interacted with methylxanthine products, such as macrolides or fluoroquinolones; and evidence of alcohol abuse. All patients were not taking theophylline at the time of recruitment in order to avoid the well-known effects of theophylline withdrawal in COPD. 13 Table 1 outlines some characteristics and the smoking history of the population studied. This was a single-blind, placebo-controlled, randomized, two-period trial. Following an initial screening visit, all eligible patients entered a 7 days inhaled placebo run-in during which their regular treatment for COPD was stopped and they received salbutamol for relief of breakthrough symptoms and inhaled corticosteroids when already used. Thereafter, all patients were treated with formoterol 12 mg bid+tiotropium 18 mg od for 4. After this first period, they were divided in two groups of 18 patients each in a random manner. Both groups continued with the initial treatment for further 4, but the first group also oral received placebo twice whereas the second group received oral theophylline (i.e., 200 or 300 mg twice daily throughout the 4 [the 300-mg dose was only for patients weighing480 kg, and these patients received 200 mg bid for first week and the higher 300-mg dose bid for the remaining 3 ]). The patients were blinded to the nature of the oral medications. After the initial screening visit, patients returned to the clinic at the end of the 7-day placebo run-in period for visit 2, at which time they started the treatment regimen with formoterol+tiotropium. Afterwards, they attended the clinic after 4 of treatment when they were randomized to placebo or theophylline, and after 4 further of treatment for evaluations of pulmonary function. Patients withheld from taking their study medication on the morning of each visit, so all measurements were made at trough (i.e., approximately 12 h after their preceding evening dose was received). At each visit, three FEV 1 and FVC measurements were taken, and the highest of each was recorded. Changes in the perception of dyspnea assessed through use of a bipolar visual anagogic scale (VAS), and supplemental salbutamol use were also monitored at each visit. The VAS consisted of a 20-cm horizontal line scoring between 0 (very much better) at the left end, and 10 (very much worse) at the right, with no change in the middle. All patients were familiarized with the VAS before the study. The supplemental salbutamol use was recorded by the patient daily throughout the 2-month treatment period. At the end of the second 4-week-treatment, we checked the serum theophylline concentration in all patients included in the theophylline arm. Adverse events were collected through non-specific questioning or direct observation by investigators at each clinic visit and through spontaneous reports by patients.
3 Effect of theophylline on a combination of formoterol and tiotropium in stable COPD 959 Table 1 Demographics of the population studied. Variables Placebo arm Theophylline arm Age (year) Sex (no.) 15 M 3 F 17 M 1 F Smoking (pack-year) Current smokers, n (%) 12 (72) 11 (61) FEV 1, predicted (%) 42 (1.7) 39 (1.4) FEV 1 /FVC ratio (before bronchodilator) Inhaled corticosteroid use, n (%) 9 (50) 11 (61) Tiotropium use, n (%) 7 (39) 6 (33) Long-acting b 2 -agonist use, n (%) 18 (100) 18 (100) Theophylline use, n (%) 2 (11) 1 (6) Data are presented as mean7se unless otherwise indicated. M, male; F, female. Patients who experienced exacerbation resulting in hospitalization or, at least, treatment with an oral corticosteroid and/or antibiotic during the study period were withdrawn. The definition of exacerbation used in the present study was a worsening of respiratory symptoms, which requires treatment with oral corticosteroids or antibiotics, or both. 14 This was a pilot study and the first known evaluation of the additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD. In view of the lack of previous experiences, no statistical hypotheses were drawn and consequently no formal sample size calculation was made. The use of a pilot study such as the current study in clinical research is a well-established scientific procedure and only through the use of a pilot study can statisticians clarify data distributions and determine appropriate sample sizes for full-scale clinical trials. 3 The primary efficacy measure was the mean change from baseline in predose FEV 1 at the end of the study. Secondary efficacy measures included change from baseline in FVC, VAS score assessing dyspnea and in supplemental salbutamol. Student s t-test for paired data and repeated ANOVA measurements were used for statistical analysis. Values of po0:05 were considered as significant. Results All patients completed the first treatment period with formoterol+tiotropium. Thirty-three patients completed the second treatment period: 17 patients in the placebo arm, and 16 patients in the theophylline arm. The patient in the placebo arm was withdrawn for COPD exacerbation resulting in hospitalization. The two patients in the theophylline were withdrawn for severe headache and rhythm disturbances, respectively. There was no significant difference among the post run-in baseline spirometric values of the two treatment groups (FEV 1, P40.05)). The mean7se baseline FEV 1 and FVC at the start of the treatment periods were L and L, respectively in the placebo arm and L and L, respectively, in the theophylline arm. Mean predose FEV 1 and FVC values significantly (Po0.001) improved compared to baseline at the end of the first 4- week treatment in both arms (Fig. 1). At the end of the second 4-week treatment, FEV 1 (Po0.001 both in the placebo arm and in the theophylline arm, respectively) and FVC (Po0.05 in the placebo arm and Po0.001 in the theophylline arm, respectively) values further significantly improved in both arms (Fig. 1). On the contrary, differences in improvements in FEV 1 and FVC between theophylline and placebo arms at the end of the second treatment period were not significant (P ¼ and P ¼ 0.638, respectively). The initial 4-week treatment with formoterol+tiotropium induced a significant (Po0.001) improvement in dyspnea and induced a significant (Po0.001) reduction in the use of supplemental salbutamol (Fig. 2). At the end of the second 4-week treatment with formoterol+tiotropium, we observed an additional significant improvement in dyspnea (Po0.01 in the placebo arm and Po0.001 in the theophylline arm, respectively) and a further significant (Po0.05, both in the placebo arm and in the theophylline arm) reduction in the use of salbutamol as rescue medication (Fig. 2). Differences in changes in dyspnea score and use of supplemental salbutamol between theophylline and placebo arms at the end of the second treatment period were not significant (P ¼ and P ¼ 0.975, respectively). In any case, 5 patients reported an important relief in dyspnea at the end the theophylline administration period. Ten out of 16 patients had a theophylline concentration above the lower limit of 10 mg/ml, only one had a serum theophylline concentration 420 mg/ml, and in the other five patients theophylline concentration was in the 7 10 mg/ ml range. A part the three patients that were withdrawn for severe adverse events, two patients in the theophylline arm suffered from a mild gastrointestinal adverse event and another from insomnia. Discussion Theophylline is still widely used as a bronchodilator in COPD, although inhaled bronchodilators are preferred. 1,2 Usually theophylline tends to be added to these inhaled bronchodilators in patients with more severe COPD. 15 In a crossover study, 16 patients with severe COPD received high-dose salbutamol followed by high-dose theophylline, and the opposite regimen. 16 The increase in FEV 1 with salbutamol
4 960 M. Cazzola, M.G. Matera 1.25 FEV 1 7 VAS 1.10 L 0.95 score FVC 5.5 Supplemental salbutamol L number of puffs Figure 1 Mean FEV 1 and FVC values during 8 of therapy with formoterol 12 mg bid+tiotropium 18 mg od plus, in the second 4-week treatment, placebo (n 17, squares) or theophylline (n 16, triangles), respectively. Values are mean7se. Po0:001 versus time point 0 (end of the run-in); y Po0:05, and yyy Po0:001 vs. 4-week time point. alone was 24% of the baseline value, versus 17% with theophylline alone. The responses to the two agents were additive regardless of which drug was given first. Interestingly, patients with reversibility to salbutamol showed a large increase in FEV 1 when theophylline was added (32% of baseline), whereas those with poorly reversible obstruction showed no additional benefit when theophylline was added. These observations raise the question of the risk benefit ratio of theophylline therapy for patients with poorly reversible obstruction. Others have recommended the opposite: that theophylline must be reserved for patients with bronchodilator irreversibility. 17 Interestingly, many studies have shown that combinations of b 2 -agonists, anticholinergic agents, and theophylline can achieve additional improvements in lung function and health status Nonetheless, Lefcoe et al. 21, who compared the bronchodilator effects of ipratropium 40 mg plus oral fenoterol 5 mg, plus oral oxtriphylline 400 mg, and ipratropium 40 mg, plus fenoterol 5 mg, plus oxtriphylline 400 mg in a double-blind, single-dose study of 15 bronchitis patients, documented that the three-drug and the fenoterol oxtriphylline regimens were not significantly better than ipratropium alone. 1.0 Figure 2 Mean VAS score and daily numbers of puffs of salbutamol as rescue medication averaged over the 7 days of the run-in period (time point 0) and over the week preceding each visit, during 8 of therapy with formoterol 12 mg bid+tiotropium 18 mg od plus, in the second 4-week treatment, placebo (n 17, squares) or theophylline (n 16, triangles), respectively. Values are mean7se. po0:001 vs. time point 0; y Po0:05, yy Po0:01 and yyy Po0:001 vs. 4-week time point. More recently, theophylline has been shown to give additional clinical improvement when added to salmeterol, 10,11 but Yildiz et al. 22 have documented that the addition of theophylline to formoterol had similar effects on St. George s Respiratory Questionnaire scores and lung functions when compared to formoterol+ipratropium. It has also been reported that the combined use of theophylline with inhaled tiotropium bromide produces better exercise capacity than the tiotropium alone in patients with stable COPD. 23 Our study documented that the addition of theophylline on a combination of formoterol and tiotropium in stable COPD did not induced a significant further improvement in lung function and in dyspnea. We must underline that this was a pilot study and, consequently, associated with an insufficient statistical power. It is likely that the failure to show a statistically significant difference between treatments when we explored the impact of different therapies on dyspnea and salbutamol use was likely associated with an insufficient statistical power in the study, although the differences between treatments were small. Obviously,
5 Effect of theophylline on a combination of formoterol and tiotropium in stable COPD 961 there was a possibility of a type II error, which supported the lack of significance that we have repeatedly observed 24 and, perhaps, a study with a larger sample would likely have reached statistical significance. In any case, our study questions the importance of adding theophylline in stable COPD patients already treated with two long-acting bronchodilators, although it indicates the possibility that some of them can benefit from theophylline because of a symptomatic improvement. A systematic review and meta-analysis of efficacy of theophylline in people with stable COPD has documented that beneficial effects may be obtained in individuals who remain symptomatic from COPD, despite first-line bronchodilator therapy. 25 We cannot confirm this finding because we have observed improvement in dyspnea in both groups, but differences between theophylline and placebo groups were not significant. In any case, the fact that five patients reported an important relief in dyspnea during the theophylline administration period and these patients were between those with more severe dyspnea at the end of the first 4-week treatment with formoterol+tiotropium supports this opinion. It is evident that larger parallel, randomized-controlled trials with explicit clinical and diagnostic criteria, sufficient duration of follow-up and description of all relevant clinical outcome measures are warranted in order to understand when the addition of theophylline is really needed. In any case, theophylline possesses anti-inflammatory and immunomodulatory effects in addition to its well-recognized effects as a bronchodilator when administered at doses that are not associated with unacceptable side effects and which may be used in selected patients without serum monitoring. 26,27 Therefore, we believe that a combination therapy with tiotropium and a long-acting b 2 -agonist may serve as a basis for improved triple therapy combinations with lowdose theophylline with the aim of delivering three complementary therapeutic effects for patients with COPD. In order to explore this possibility, a trial of longer duration (at least 1 year) is mandatory. References 1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2005 [accessed August 26, 2006]. Available at: / 2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23: Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17: Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98: Cazzola M, Noschese P, Salzillo A, De Giglio C, D Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005;99: van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26: van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129: Tashkin D, Celli B, Decramer M, Burkhart D, Kesten S, Cassino C. Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trial [abstract]. Proc Am Thorac Soc 2006;3:A Cazzola M, Matera MG, Donner CF. Long-acting b 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 1999;54: Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000;118: ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119: Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005;2: Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993;104: Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000;320: Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005; 2: Filuk RB, Easton PA, Anthonisen NR. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132: Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 1992;101: Nishimura K, Koyama H, Ikeda A, Izumi T. Is oral theophylline effective in combination with both inhaled anticholinergic agent inhaled b2-agonist in the treatment of stable COPD? Chest 1993;104: Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled b-agonist, and the combination of all three in patients with COPD. Chest 1994;105: Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107: Lefcoe NM, Toogood JH, Blennerhassett G, Baskerville J, Paterson NA. The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis: a double-blind single dose study. Chest 1982;82(3): Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Different bronchodilator combinations have similar effects on health status in COPD. Pulm Pharmacol Ther 2006;19: Hanaoka Y, Teramoto S, Yamamoto H, Yamaguchi Y, Ouchi Y. Effects of the sustained release of theophylline, UnifilR, and tiotropium bromide on pulmonary function and exercise performance in patients with stable chronic obstructive pulmonary disease [abstract]. Proc Am Thorac Soc 2006; 3:A Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of b, the type II error, and sample size in the design and interpretation of the randomized controlled trial. In: Bailar JC,
6 962 M. Cazzola, M.G. Matera Mosteller F, editors. Medical uses of statistics. Boston, USA: NEJM Books; p Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and metaanalysis. Respir Med 2005;99: Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Antiinflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343: Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:
Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni, MD
Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD* Mario Cazzola, MD, FCCP; Gabriele Di Lorenzo, MD; Felice Di Perna, MD; Francesco Calderaro, MD; Renato Testi, MD; and Stefano Centanni,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationAclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
Send Orders of Reprints at bspsaif@emirates.net.ae 150 The Open Respiratory Medicine Journal, 2012, 6, 150-154 Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Charlotte Suppli
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA meta-analysis on the efficacy of oral theophylline in patients with stable COPD
ORIGINAL RESEARCH A meta-analysis on the efficacy of oral theophylline in patients with stable COPD Néstor A Molfino Peter Zhang Otsuka Maryland Research Institute, Rockville, MD, USA Background: Theophylline
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationThe physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer
Eur Respir Rev 2006; 15: 99, 51 57 DOI: 10.1183/09059180.00009906 CopyrightßERSJ Ltd 2006 Tiotropium as essential maintenance therapy in COPD M. Decramer ABSTRACT: Over the past decade, several large-scale
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationPharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Eur Respir J 2002; 19: 639 644 DOI: 10.1183/09031936.02.00238002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Pharmacodynamic steady state
More informationLong-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium
Eur Respir J 2; 15: 878±885 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 2 European Respiratory Journal ISSN 93-1936 Long-term treatment of chronic obstructive pulmonary disease with
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationTolerance to bronchodilating effects of salmeterol in COPD
Respiratory Medicine (2003) 97, 1014 1020 Tolerance to bronchodilating effects of salmeterol in COPD J.F. Donohue a, *, S. Menjoge b, S. Kesten b a University of North Carolina School of Medicine, 130
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationBronchodilator Reversibility in COPD
CHEST Special Features Bronchodilator Reversibility in COPD Nicola A. Hanania, MD, FCCP ; Bartolome R. Celli, MD, FCCP ; James F. Donohue, MD, FCCP ; and Ubaldo J. Martin, MD, FCCP COPD is a preventable
More informationComparing COPD Treatment: Nebulizer, Metered Dose Inhaler, and Concomitant Therapy
The American Journal of Medicine (2007) 120, 435-441 CLINICAL RESEARCH STUDY Comparing COPD Treatment:, Metered Dose, and Concomitant Therapy Donald P. Tashkin, MD, a Gerald L. Klein, MD, b,c Shoshana
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial
Respiratory Medicine (2008) 102, 479 487 Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial Donald P. Tashkin a,, Michael Littner b, Charles
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSeveral decades ago, the choices for the management
A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol* James F. Donohue, MD, FCCP; Jan A. van Noord, MD, PhD; Eric
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationNew Drug Evaluation: Olodaterol oral inhalation solution (Striverdi Respimat)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEffect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD
Respiratory Medicine (2006) 100, 212 217 Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD M. Cazzola a,, P. Noschese a, F. De Michele b, G.
More informationOutcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
ORIGINAL RESEARCH Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids Richard Hodder 1 Steven Kesten 2 Shailendra Menjoge 2 Klaus Viel 3 1 Divisions
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationEffect of theophylline associated with short-acting or long-acting inhaled β 2
1 Original Article Effect of associated with short-acting or long-acting inhaled in patients with stable chronic obstructive pulmonary disease: a systematic review* Eliane Cristina Zacarias 1, Aldemar
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationCOPD is a significant cause of mortality
RESPIRATORY CLINICAL FOCUS Comparing the range and costs of COPD treatments in primary care Practice nurses should familiarise themselves with the many products available for the management of chronic
More informationBronchodilator responsiveness in patients with COPD
Eur Respir J 28; 31: 742 75 DOI: 1.1183/931936.12967 CopyrightßERS Journals Ltd 28 Bronchodilator responsiveness in patients with COPD D.P. Tashkin*, B. Celli #, M. Decramer ", D. Liu +, D. Burkhart +,
More informationEffect of add-on therapy of tiotropium in COPD treated with theophylline
ORIGINAL RESEARCH Effect of add-on therapy of tiotropium in COPD treated with theophylline Tomotaka Kawayama 1 Tomoaki Hoshino 1 Masao Ichiki 2 Toru Tsuda 3 Masaharu Kinoshita 4 Shohei Takata 5 Takeharu
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Abstract Whittaker C, BPharm, MRPharmS Amayeza Info Centre Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationUtilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during
Utilization of LABAs versus SABAs in Albanian Insured Outpatients with COPD during 2008-2012 Doi:10.5901/mjss.2013.v4n9p573 Abstract Alida Sina PhD Student, Health Insurance Institute, Tirana, Albania
More informationC hronic obstructive pulmonary disease (COPD) is currently
854 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis R G Barr, J Bourbeau, C A Camargo, F S F Ram... See end of article for authors affiliations...
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationTotal reversibility testing as indicator of the clinical efficacy of formoterol in COPD $
Respiratory Medicine (2005) 99, 695 702 Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD $ Mathieu Molimard a,, Jacques Bourcereau b, Vincent Le Gros c, Isabelle
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationThe Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia. Rennard, Stephen I; Sin, Donald D; Tashkin, Donald P; Calverley, Peter M; Radner, Finn Published in: Annals
More informationLong-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial
Eur Respir J 2010; 35: 287 294 DOI: 10.1183/09031936.00082909 CopyrightßERS Journals Ltd 2010 Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial D.P. Tashkin*, B. Celli
More informationThe beneficial effects of ICS in COPD
BIOLOGY AND HEALTH Journal website: www.biologyandhealth.com Narrative review The beneficial effects of ICS in COPD Stacha Reumers Stacha Reumers I6111431 Maastricht University Faculty of Health, Medicine
More informationJournal of the COPD Foundation
132 Predictors of Change in SGRQ Score Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Baseline Severity as Predictor of Change in St George s Respiratory Questionnaire
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become
More informationAclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A15-06 Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aclidiniumbromid/Formoterol
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More information-agonists (LABA) in chronic obstructive pulmonary disease: effi cacy and safety
REVIEW Long-acting -agonists (LABA) in chronic obstructive pulmonary disease: effi cacy and safety Andrea Rossi 1 Sonia Khirani 1 Mario Cazzola 2 1 Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo,
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationAdvances in Chronic Obstructive Pulmonary Disease
Advances in Chronic Obstructive Pulmonary Disease By Dave C. Todd, MD; and Darcy D. Marciniuk, MD, FRCPC The case of Nina Nina, 64, presents to the clinic with a three- to fouryear history of progressive,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationPublisher: Taylor & Francis. Journal: Expert Review of Clinical Pharmacology. DOI: / Drug Profile
1 Publisher: Taylor & Francis Journal: Expert Review of Clinical Pharmacology DOI: 10.1586/17512433.2016.1169173 Drug Profile Aclidinium bromide inhalation powder for the long-term, maintenance treatment
More informationEfficacy of Once-Daily Indacaterol Relative to Alternative Bronchodilators in COPD: A Patient-Level Mixed Treatment Comparison
VALUE IN HEALTH 15 (2012) 524 533 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Comparative Effectiveness Research/Health Technology Assessment Efficacy of Once-Daily
More informationImpacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur Respir Rev 2006; 15: 99, 37 41 DOI: 10.1183/09059180.00009903 CopyrightßERSJ Ltd 2006 Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance D.E. O Donnell ABSTRACT: The
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMinimal important difference of the transition dyspnoea index in a multinational clinical trial
Eur Respir J 2003; 21: 267 272 DOI: 10.1183/09031936.03.00068503a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Minimal important difference
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationBlood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationD DAVID PUBLISHING. 1. Introduction
Journal of Health Science 2 (2014) 591-598 doi: 10.17265/2328-7136/2014.12.004 D DAVID PUBLISHING Comparative Efficacy and Safety of Two Formulations of Ipratropium Bromide (IB) HFA pmdi in Patients with
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationDisease progression in COPD:
Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationExternal validity of randomized controlled trials in COPD
Respiratory Medicine (2007) 101, 1313 1320 External validity of randomized controlled trials in COPD Justin Travers a, Suzanne Marsh a, Brent Caldwell a, Mathew Williams a, Sarah Aldington a, Mark Weatherall
More informationDrug Class Review on Beta 2 -Agonists
Drug Class Review on Beta 2 -Agonists Final Report s November 2006 The Agency for Healthcare Research and Quality has not seen or apporved this report A literature scan of this topic is done periodically.
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationLong-Term Management of Chronic Obstructive Pulmonary Disease
CHAPTER 35 Long-Term Management of Chronic Obstructive Pulmonary Disease P. S. Shankar Introduction Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease associated with longterm exposure
More informationRakan M. Haddad MD*, Sultan K. AlSureehein MD*, Ghaith Abu Alsamen MD*, Yazan M. Khair MD*, Mohammed M. Al-Najada MD*, Jafar A.
Efficacy and safety of oral low dose Theophylline in Jordanian patients with stable Chronic Obstructive Pulmonary Disease treated at King Hussein Medical Center Rakan M. Haddad MD*, Sultan K. AlSureehein
More informationCombination therapy in COPD: different response of COPD stages and predictivity of functional parameters
European Review for Medical and Pharmacological Sciences 2005; 9: 209-215 Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters C. TERZANO, A. PETROIANNI,
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationEvaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $
Respiratory Medicine (2006) 100, 2190 2196 Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore $ Kang-Hoe
More informationPulmonary Pharmacology & Therapeutics
Pulmonary Pharmacology & Therapeutics 31 (2015) 85e91 Contents lists available at ScienceDirect Pulmonary Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/ypupt Daily variation in
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More information